The purpose of this study is to learn more about the use of an investigational drug, called NV-5138, for the treatment of treatment-resistant depression. We want to determine if NV-5138 can help to improve the symptoms of people with treatment-resistant depression. People with treatment-resistant depression have been prescribed antidepressants for depression (specifically major depressive disorder) previously, but their symptoms have not improved.
CONTACT US ABOUT DEPRESSION TRIALTreatment Resistant Depression
Description
Eligibility Criteria
18-70 Years Old; Has a Body Mass Index (BMI) between 19.0 to 40 kg/m²; Has a diagnosis of Major Depressive Disorder (MDD); Has a history of inadequate response to ≥1 but ≤4 prior antidepressant treatment therapies
Duration
Up to 15 weeks total (including Screening and Safety Follow-up Periods)
Intervention
800 mg or 1600 mg capsules of NV-5138 or matching placebo, ingested orally approximately 3 hours after breakfast
Compensation
$60/Visit
Categories
- Adult Clinical Trial